Merck, Now No. 2 Drugmaker, Set for Future Buys

The new Merck & Co. has become the world's second-biggest drugmaker overnight with a huge acquisition, but it still has a fat wallet and plans more wheeling and dealing.

A day after closing its $41.1 billion purchase of longtime joint venture partner Schering-Plough Corp., Merck already is looking to increase the number of acquisitions and licensing deals it does, Chief Executive Richard Clark said Wednesday. The company has averaged 50 deals a year since 2003.

"We'll actually do more and maybe even try to double it," he told The Associated Press exclusively.

Clark said Merck is looking to make deals with "biotech companies that have first or best-in-class products that can build our franchises."

It has about $8 billion in cash and investments to spend.

Wall Street liked the Schering deal, pushing Merck shares up $1.97, or 6.4 percent, to end at $32.64 Wednesday, making it the top gainer among the Dow Jones industrial average components.

"We've got a tremendous pipeline, with 15 late-stage candidates," Clark said.

Between those drugs and future deals, Merck is focusing on several areas, including its longtime strengths such as cardiovascular disease — with four new drugs in testing — and vaccines, adding Schering-Plough's experimental shot to prevent staph infections to Merck's array of standard child and adult vaccines.

Other targets are osteoporosis medicines, such as a Merck drug to replace its pioneering Fosamax, which has lost sales to generic competition, and women's health, as Schering makes contraceptive and fertility drugs.

With the Schering deal, Merck leapfrogged from No. 8 to No. 2 in the industry by revenue, behind Pfizer Inc. — despite Clark insisting he opposed such a megadeal since he took Merck's helm in 2005. Merck, of Whitehouse Station, N.J., and New York's Pfizer, which last month bought Wyeth for $68 billion, are now back in the positions they held a decade ago.